Xortx Therapeutics (TSE:XRTX) has released an update.
Xortx Therapeutics Inc. has had its financial statements for the years ending December 31 of 2021, 2022, and 2023 audited by an independent registered public accounting firm, which concluded the statements to be fairly presented in conformity with International Financial Reporting Standards. The company, which has changed its presentation currency to the U.S. dollar from the Canadian dollar as of January 1, 2023, reports a decrease in total assets from the previous year. No critical audit matters were identified in the current period audit of the consolidated financial statements.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
